Within 5 short years of release, approximatly 20% of antibiotics become subject to resistance from bacterial pathogens which means that antibiotic proliferation is chronologically limited within its life expectancy. Coupled with this, if an antibiotic is highly effective, the scientific and medical community often rally against its usage so that such a tool can be saved in reserve for a global bacterial pandemic. In either scenario, return upon investment is less than what it would be with a different class of medication (e.g. selective serotonin re-uptake inhibitor, statin, hypnotic etc.) which is why pharmaceutical organizations are less interested in research and development dedicated to antibiotic medicine in favor of other, more profitable medication categories. This lack of investment however is myopic and will inevitably backfire upon the pharmaceutical industry as a whole if new antibiotics are not developed because medications used to treat cancer will become less in demand due to the fact that cancer patients are highly likely to acquire an infection during treatment when their immune system is comprised, with this infection often killing the patient if antibiotic solutions are not available. This would expectedly lead to a sharp decline in cancer medication treatment and subsequently pharmaceutical sales of related medications as patients would be likely to adopt living the rest of their life as fully as possible and forgoing treatment as they would be damned if they accept the cancer treatment and develop an infection which kills them but also damned if they don’t accept the treatment and let the cancer run its course which is almost always fatal. To provide comparison of the research, development, and manufacturing contrast between oncology medications and antibiotics, as of 2020, there are currently 800 medications in development for cancer and hypertension whilst only 28 antibiotic medications undergoing that same research phase and development process, with 2 of these antibiotics expected to become fully developed and able to reach the market and patients. The last new antibiotic class, lipopeptides, were introduced in 1984 with a gap referred to as an “antibiotic void” occurring during the 1990’s, 2000’s, 2010’s, and now moving into the 2020’s. The urgency of this threat is projected to become dire within the coming decades, with scientists predicting that by 2050, medicine could potentially come full circle to the pre-antibiotic era, with microbes which are completely and totally resistant to every antibiotic known to medicine